A method for accurate quantification and profiling of viable bacterial communities in complex low-biomass samples

Background

The study of microbial communities, or microbiomes, has become an essential field in both environmental and biomedical research. Understanding the composition and function of these communities is crucial for insights into health, disease, and ecosystem dynamics. However, a persistent challenge in microbiome analysis is accurately distinguishing between live (viable) and dead (nonviable) bacteria within complex samples, especially in environments with low microbial biomass such as human skin or built surfaces. Traditional DNA-based sequencing methods, such as 16S rRNA gene amplicon sequencing, detect both viable and nonviable bacterial DNA, leading to potential overestimation of microbial diversity and abundance. This limitation hinders our ability to interpret the true biological relevance of microbiome data, as only viable bacteria are capable of interacting with their environment or host.

Current approaches to assess bacterial viability, such as quantitative PCR (qPCR) and culture-based methods, have significant drawbacks. qPCR typically requires high amounts of DNA and does not provide absolute quantification, making it unreliable for low-biomass samples. Culture-based techniques, while specific to viable organisms, are labor-intensive, time-consuming, and biased toward bacteria that can grow under laboratory conditions, thus failing to capture the full spectrum of viable community members. Furthermore, traditional sequencing of swabbed samples from surfaces like skin often results in a substantial overestimation of viable bacterial richness and diversity, as most detected DNA originates from dead cells. These shortcomings highlight the need for more accurate, sensitive, and quantitative methods to assess bacterial viability and community structure, particularly in samples where the majority of bacterial DNA may not represent living organisms.

Technology

This technology enables precise assessment of bacterial viability and community composition by integrating propidium monoazide (PMA) treatment with droplet digital PCR (ddPCR) and 16S rRNA gene sequencing. The process begins by splitting a microbial sample into two aliquots, treating one with PMA—a dye that selectively penetrates only membrane-compromised, nonviable cells and irreversibly binds their DNA upon blue light activation. This binding prevents amplification of nonviable DNA during PCR. DNA is then extracted from both aliquots and quantified using ddPCR, which allows for absolute DNA quantification even in low-biomass samples. By comparing DNA quantities between the PMA-treated and untreated samples, a viability score is calculated. Further, sequencing the 16S rRNA gene from the PMA-treated sample provides a species-level profile of the viable bacterial community, distinguishing live from dead bacterial taxa.

The differentiation of this technology lies in its ability to provide absolute quantification and species-level resolution of viable bacteria in both high- and low-biomass environments, such as human skin or environmental surfaces, where traditional methods often fail. Unlike conventional qPCR or sequencing, which cannot distinguish between DNA from live and dead bacteria and tend to overestimate viable populations, this approach accurately reflects the true viable microbiome. Validation studies demonstrate a strong correlation with culturable colony-forming units and reveal that traditional sequencing dramatically overestimates both the abundance and diversity of viable bacteria, especially on skin surfaces. The method’s compatibility with standard laboratory equipment, its robustness across sample types, and its capacity to resolve viability at the species level make it a powerful and versatile tool for microbiome research, clinical diagnostics, and environmental monitoring.

Benefits

• Accurate absolute quantification of viable bacteria, even in low-biomass samples
• Selective exclusion of DNA from nonviable cells using PMA treatment
• Species-level profiling of viable bacterial communities via 16S rRNA sequencing
• Improved correlation with culturable bacterial counts compared to traditional methods
• Applicable to diverse sample types including human and mouse microbiomes and built environments
• Enables distinction between viable and nonviable bacterial populations for better microbiome analysis
• Robust, reproducible method compatible with standard laboratory protocols and equipment
• Facilitates deeper understanding of microbial community dynamics and host-microbe interactions

Applications

• Clinical skin infection diagnostics
• Environmental surface contamination monitoring
• Probiotic product efficacy testing
• Hospital-acquired infection surveillance
• Personal care product microbiome studies

Additional info

This methodology integrates propidium monoazide (PMA) treatment with droplet digital PCR (ddPCR) and 16S rRNA sequencing to quantify viable bacteria. PMA selectively cross-links DNA in membrane-compromised cells via blue light, blocking amplification. Comparing DNA quantities from PMA-treated and untreated aliquots provides absolute viability scores. Subsequent sequencing identifies specific viable taxa, enabling precise community profiling in low-biomass environments, such as human skin, where standard methods overestimate microbial diversity.